Esther Serra, Cristina Campo, Zoltan Novák, Bernardetta Majorek-Olechowska, G Pulka, Aintzane García-Bea & Luis Labeaga (2019)
Journal of Dermatological Treatment
An exploratory study evaluated the efficacy and safety of bilastine, an H1-antihistamine, in reducing pruritus in patients with chronic spontaneous urticaria and other pruritic skin diseases.
This multicenter, open-label, exploratory study, included patients with chronic spontaneous urticaria, eczema/dermatitis, prurigo or cutaneous pruritus who received 20 mg of H1-antihistamine bilastine once daily for 8 days, or 40 mg if non-responder after first week.
The analysis revealed that pruritus severity score from baseline to week 8 was reduced with H1-antihistamine bilastine (overall and by disease group) in both responders and non-responders. Bilastine improved the Dermatology Life Quality Index at weeks 4 and 8 in all disease groups, and the 7-day Urticaria Activity Score in Chronic Spontaneous Urticaria patients.
Conclusively, H1-antihistamine bilastine was well tolerated and relieved pruritus associated with urticaria and other skin diseases, with a very good safety profile.